Edition:
United Kingdom

Denali Therapeutics Inc Reports Q3 Loss Per Share Of $0.38


Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Denali Therapeutics Inc ::DENALI THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS AND ANNOUNCES THE APPOINTMENT OF JENNIFER COOK TO BOARD OF DIRECTORS.DENALI THERAPEUTICS INC QTRLY COLLABORATION REVENUE WAS $1.2 MILLION.DENALI THERAPEUTICS INC QTRLY LOSS PER SHARE $0.38. 

Company Quote

24.27
 --
25 Apr 2019